Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
TGN1412: From Discovery to Disaster.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Mitoxantrone-induced suicidal erythrocyte death.
Food and Drug Administration drug insert for Campath (alemtuzumab)
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
A meta-analysis of whole genome linkage screens in multiple sclerosis.

Pages